“Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, With Rapid Improvement Following IL-17A IL-17F Blockade by Bimekizumab”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): 1987-92. https://doi.org/10.25251/skin.8.6.13.